Table 2.
Some reported incidences of JAK2 V61F mutation in myeloproliferative disorders
| Investigators | ||||||||
|---|---|---|---|---|---|---|---|---|
| Disorder | Green17 | Vainchenker14 | Gilliland16 | Skoda15 | Tefferi24 | Cross22 | Zhao25 | Jelinek23 |
| PV | 97% | 88% | 74% | 65% | 81% | 83% | 86% | |
| ET | 57% | 43% | 32% | 23% | 41% | 30% | ||
| IMF | 50% | 43% | 35% | 57% | 43% | 95% | ||
| SM | 25% | 0% | ||||||
| CNL | 17% | 33% | ||||||
| HES | 0% | 2% | ||||||
| UN | 20% | |||||||
| MDS | 5% | 1.5% | ||||||
| CMML | 3% | 13% |
KEY TO ABBREVIATIONS
PV: polycythemia vera, ET: essential thrombocythemia, IMF: idiopathic myelofibrosis, SM: systmemic mastocytosis, CNL: chronic neutrophilic leukemia, HES: hypereosinophilic syndrome, UN: unclassified MPD, MDS: myelodysplastic syndrome, CMML: chronic myelomonocytic leukemia.